The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer

Details

Serval ID
serval:BIB_7DD7EDB0443E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer
Journal
Nuclear Medicine Communications
Author(s)
Prior  J. O., Barghouth  G., Delaloye  J. F., Leyvraz  S., Bischof Delaloye  A.
ISSN
0143-3636 (Print)
Publication state
Published
Issued date
01/2003
Volume
24
Number
1
Pages
29-36
Notes
Clinical Trial
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jan
Abstract
This prospective study evaluates bone marrow scintigraphy (BMS) in detecting bone metastases from primary breast cancer when performed in complement to conventional bone scan (BS). Sixty women predominantly with low-stage disease underwent BS followed by BMS within 1-35 days using BW250/183 antigranulocyte antibodies. A receiver operating characteristic (ROC) analysis was performed to compare BS to BS+BMS on a patient-by-patient basis using a 'gold standard' composed of subsequent computed tomography, magnetic resonance imaging, X-ray or BS examinations and at least a 12 month follow-up. Metastases were present in eight out of 60 patients (13%). Specificity was improved by BS+BMS compared to BS alone (90%, 65%) as well as positive predictive value (62%, 27%), accuracy (87%, 72%), positive (10.4, 2.4) and negative (0.20, 0.00) likelihood ratios. Sensitivity (100%, 88%) and negative predictive value (100%, 97%) were similar for BMS+BS and BS alone. As a result of BMS, clinical management was modified in 15 patients (25%). In conclusion, BMS supplements BS by improving specificity, positive predictive value and accuracy in detecting breast cancer bone metastases. The ROC curves show improved specificity for BS+BMS at the same sensitivity compared to BS alone. Consequently, BMS may be useful in low-stage subjects with positive or equivocal BS for metastases.
Keywords
Adult Aged Aged, 80 and over Antibodies, Monoclonal/*diagnostic use Bone Marrow/radionuclide imaging Bone Neoplasms/diagnosis/*radionuclide imaging/*secondary Bone and Bones/radionuclide imaging Breast Neoplasms/*diagnosis/radionuclide imaging False Negative Reactions False Positive Reactions Female Humans Middle Aged Quality Control ROC Curve Radiopharmaceuticals/diagnostic use Whole-Body Counting
Pubmed
Web of science
Create date
28/01/2008 9:32
Last modification date
20/08/2019 15:39
Usage data